secwatch / observer
8-K filed June 2, 2026, 4:07 PM ET ticker EVMN CIK 0002044725
other confidence high sentiment neutral materiality 0.15

Evommune stockholders elect Peña and Bauer as directors, ratify BDO auditor

Evommune, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Evommune, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-06-02 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-02
Exact text from the filing
Proposal 2 – Ratification of Selection of Independent Registered Public Accounting Firm The proposal to ratify the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved based upon the following votes: For Against Abstain Broker Non-Votes 24,664,299 430 29,765 —
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Evommune, Inc. shareholders approved Election of Directors at the 2026-06-02 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-02
Exact text from the filing
Proposal 1 – Election of Directors The following nominees were elected to the Company’s Board of Directors to hold office until the Company's 2029 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified, or until their earlier death, resignation or removal. The votes cast at the Annual Meeting were as follows: Nominee For Withheld Broker Non-Votes Luis Peña 21,859,596 1,949,148 885,750 Eugene Bauer, M.D. 23,637,920 170,824 885,750
View on SEC.gov

222 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Evommune, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-26-253482
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.